Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (4373)	7/28/2001 11:28:16 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Hi Bernard, Clearly, there's a large number of investors using TA to some degree; and it seems a large number of professionals may use it to a large degree. I agree that it's a factor. I think some fundamental information has affected SCIO and other Biotechs during the past couple days. On Thursday, there was a spate of FDA approvals. I think this removed some FDA uncertainty raising all boats with imminent or nearly so approvals. Then on Friday, the AVIR screwup, brought back some of that FDA uncertainty. RE SCIO specifically, I don't expect it to go above 25 before the final FDA approval within the next 2-3 weeks; and then only if the Street likes the label. If all goes very, very well, we might then see the after hours high of about $35 taken out. (From the day of the AC approval). And I don't believe that any TA guru would predict that price any time soon. ... which is why I like FA over TA most of the time. :^). Have a good weekend, Ian